G11 Stock Overview
Operates as a specialty pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pharmadrug Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.049 |
| 52 Week Low | CA$0.0005 |
| Beta | 2.69 |
| 11 Month Change | -90.00% |
| 3 Month Change | -92.86% |
| 1 Year Change | -97.30% |
| 33 Year Change | -99.69% |
| 5 Year Change | n/a |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| G11 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.1% |
| 1Y | -97.3% | -19.0% | 7.2% |
Return vs Industry: G11 underperformed the German Pharmaceuticals industry which returned -18.3% over the past year.
Return vs Market: G11 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| G11 volatility | |
|---|---|
| G11 Average Weekly Movement | 1,212.8% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G11's weekly volatility has increased from 713% to 1213% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Robert Steen | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Pharmadrug Inc. Fundamentals Summary
| G11 fundamental statistics | |
|---|---|
| Market cap | €1.09m |
| Earnings (TTM) | -€8.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs G11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G11 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$13.17m |
| Earnings | -CA$13.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -107.3% |
How did G11 perform over the long term?
See historical performance and comparison